Balance Sheet
Cash Flow Statement
Cash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Coya Therapeutics (COYA) Net Cash Flow (2022 - 2025)

Coya Therapeutics (COYA) has disclosed Net Cash Flow for 4 consecutive years, with $18.7 million as the latest value for Q4 2025.

  • Quarterly Net Cash Flow rose 156.69% to $18.7 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $9.0 million through Dec 2025, up 57.52% year-over-year, with the annual reading at $8.5 million for FY2025, 48.49% up from the prior year.
  • Net Cash Flow hit $18.7 million in Q4 2025 for Coya Therapeutics, up from -$1.1 million in the prior quarter.
  • In the past five years, Net Cash Flow ranged from a high of $21.7 million in Q4 2023 to a low of -$5.8 million in Q2 2025.
  • Historically, Net Cash Flow has averaged $2.7 million across 4 years, with a median of -$1.4 million in 2022.
  • Biggest five-year swings in Net Cash Flow: skyrocketed 900.12% in 2023 and later crashed 1085.74% in 2025.
  • Year by year, Net Cash Flow stood at -$2.7 million in 2022, then surged by 900.12% to $21.7 million in 2023, then plummeted by 66.5% to $7.3 million in 2024, then surged by 156.69% to $18.7 million in 2025.
  • Business Quant data shows Net Cash Flow for COYA at $18.7 million in Q4 2025, -$1.1 million in Q3 2025, and -$5.8 million in Q2 2025.